AI/ML Innovations raises $2.87M through convertible debentures
What's the deal? AI/ML InnovationsDealroom has a profile for this one. Try Dealroom → Inc., a Toronto-based company listed on the Canadian Securities Exchange, has closed a two-tranche private placement raising C$2,867,500 in convertible debentures. The company announced the second and final tranche of C$1,917,500 on May 11, completing a non-brokered offering. Company insiders purchased C$340,000 worth of the debentures.
The debentures can be converted into units at C$0.05 each, with every unit comprising one common share and one warrant. Each warrant lets holders buy an additional share at C$0.15 for 36 months. The debentures carry 10% annual interest and mature on May 11, 2029.
Why now? The offering comes as AIML trades at just C$0.032 on the Tradegate exchange — down nearly 12% — suggesting the company needs fresh capital to fund operations. The C$0.05 conversion price sits above the current trading level, giving the company some room if shares recover.
What could go wrong? The deal structure carries dilution risk. If all debentures convert, AIML would issue over 57 million new shares plus an equal number of warrants. For a micro-cap stock already trading in penny territory, that's a significant overhang.
Insider participation of C$340,000 triggered related-party transaction rules under Canadian securities regulations, though the company claims exemptions from formal valuation and minority shareholder approval requirements.
The offering still needs final approval from the Canadian Securities Exchange.
The signal: Despite its name suggesting broad AI ambitions, AI/ML Innovations is specifically focused on AI-driven ECG solutions for cardiovascular diagnostics — a niche where clinical validation and regulatory approvals demand sustained capital. Raising C$2.87M through convertible debentures at a conversion price above the current share price underscores how micro-cap healthtech firms listed on junior exchanges are struggling to attract conventional venture funding, even as larger AI health startups command significant valuations.
Read more: finanznachrichten.de
